IDH2 mutations are frequently observed in several types of cancer, particularly in acute myeloid leukemia (AML), where they occur in about 8-19% of cases. They are also found in gliomas, cholangiocarcinoma, and some types of sarcomas. The presence of IDH2 mutations can have diagnostic, prognostic, and therapeutic implications.
